Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 17/20 | 0.59 |
| ▸ | BCL2 | P10415 | 15/20 | 0.55 |
| ▸ | BAD | Q92934 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9952377 | 1.00 | BCL2L1 (0.59) | BCL2L1BCL2BAD | |
| SCHEMBL10166317 | 0.91 | BCL2 (0.62) | BCL2L1BCL2 | |
| SCHEMBL15338146 | 0.91 | BCL2 (0.62) | BCL2L1BCL2 | |
| SCHEMBL9950665 | 0.90 | BCL2L1 (0.65) | BCL2L1BCL2 | |
| SCHEMBL9950663 | 0.90 | BCL2L1 (0.65) | BCL2L1BCL2 | |
| SCHEMBL10166332 | 0.87 | BCL2 (0.64) | BCL2L1BCL2 | |
| SCHEMBL9951890 | 0.85 | BCL2L1 (0.62) | BCL2L1BCL2BAD | |
| SCHEMBL9951886 | 0.85 | BCL2L1 (0.62) | BCL2L1BCL2BAD | |
| SCHEMBL9951669 | 0.84 | BCL2 (0.67) | BCL2L1BCL2 | |
| SCHEMBL15958415 | 0.84 | BCL2L1 (0.57) | BCL2L1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809352-B2 | Sulfonamides as inhibitors of Bcl-2 family proteins for the treatments of cancer | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-8809352-B2 | Sulfonamides as inhibitors of Bcl-2 family proteins for the treatments of cancer | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-8809352-B2 | Sulfonamides as inhibitors of Bcl-2 family proteins for the treatments of cancer | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | BCLAF1, BCL2L11, BCL2 | BCL2L1 4/4885BCL2 3/4885BAD 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.